YM872: A selective, potent and highly water-soluble α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist

CNS Drug Reviews

Volumn 8, Issue 4, 2002, Pages 337-352

  Takahashi, Masayasu ^a   Kohara, Atsuyuki ^a   Shishikura, Jun ichi ^a   Kawasaki Yatsugi, Sachiko ^a   Ni, Jian Wei ^a   Yatsugi, Shin ichi ^a   Sakamoto, Shuichi ^a   Okada, Masamichi ^a   Shimizu Sasamata, Masao ^a   Yamaguchi, Tokio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

AMPA receptor antagonist; Focal cerebral ischemia; Neuroprotection; Stroke

Indexed keywords

6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR AGONIST; BENZODIAZEPINE; IONOTROPIC RECEPTOR; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID;

ARTERY OCCLUSION; BEHAVIOR DISORDER; CAT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MIDDLE CEREBRAL ARTERY; NEPHROTOXICITY; NERVE CELL LESION; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; RAT; REVIEW; SIDE EFFECT;

EID: 0036963806     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2002.tb00232.x     Document Type: Review

References (51)

1. Bannan PE, Graham DI, Lees KR, McCulloch J. Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res 1994;664:271-275.
2. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke 1986;17:472-476.
3. 3H]-kainic acid receptor binding by divalent cations correlates with ion affinity for the calciumn channel. Neuropharmacology 1987;26:1247-1251.
4. Buchan AM, Slivka A, Xue D. The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke. Brain Res 1992;574:171-177.
5. Bullock R, Graham DI, Chen MH, Lowe D, McCulloch J. Focal cerebral ischaemia in the cat: Pretreatment with a competitive NMDA antagonist, D-CPPene. J Cereb Blood Flow Metab 1990;10:668-674.
6. Bullock R, Graham DI, Swanson S, McCulloch J. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 1994;14:466-471.
7. l) and the concentration of inhibitor which causes 50% inhibition of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
8. 3H]NMDA as ligands for NMDA receptors in crude postsynaptic densities from rat brain. Eur J Pharmacol 1987;133: 291-300.
9. DeGraba TJ, Ostrow PT, Grotta JC. Threshold of calcium disturbances after focal cerebral ischemia in rats. Implications of the window of therapeutic opportunity. Stroke 1993;24:1212-1217.
10. Garcia JH, Liu KF, Ho KL. Neuronal necrosis after middle cerebral artery occlusion in rats progresses at different time intervals in the caudoputamen and cortex. Stroke 1995;26:636-643.
11. Gill R, Brazell C, Woodruff GN, Kemp JA. The neuroprotective action of Dizocilpine (MK-801) in the rat middle cerebral artery occlusion model of focal ischaemia. Br J Pharmacol 1991;103:2030-2036.
12. Gill R, Nordholm L, Lodge D. The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline (NBQX) in a rat focal ischaemia model. Brain Res 1992;580:35-43.
13. Gotoh O, Asano T, Koide T, Takamura K. Ischemic brain edema following occlusion of the middle cerebral artery in rats: Time courses of brain water, sodium and potassium contents and blood-brain barrier permeability. Stroke 1985;16:101-109.
14. Graham DI. Focal cerebral infarction. J Cereb Blood Flow Metab 1988;8:769-773.
15. Graham SH, Chen J, Lan JQ, Simon RP. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia. J Pharmacol Exp Ther 1996;276:1-4.
16. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 1991;252:851-853.
17. 3H]-AMPA, a structural analogue of glutamic acid, to rat brain membranes. J Neurochem 1982;38:173-178.
18. Kawabata S, Tsutsumi R, Kohara A, Yamaguchi T, Nakanishi S, Okada M. Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors. Nature 1996;383:89-92.
19. Kohara A, Okada M, Tsutsumi R, et al. In vitro characterization of YM872: A selective, potent and highly water-soluble α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor antagonist. J Pharm Pharmacol 1998;50:795-801.
20. Lo EH, Pan Y, Matsumoto K, Kowall NW. Blood-brain barrier disruption in experimental focal ischemia: Comparison between in vivo MRI and immunocytochemistry. Magn Res Imaging 1994; 12:403-411.
21. Lo EH, Hara H, Rogowska J, et al. Temporal correlation mapping analysis of the hemodynamic penumbra in mutant mice deficient in endothelial nitric oxide synthase gene expression. Stroke 1996;27:1381-1386.
22. Lo EH, Rogowska J, Batchelder K, Wolf GL. Hemodynamic alterations in focal cerebral ischemia: Temporal correlation analysis for functional imaging. Neurol Res 1996;18:150-156.
23. 2+ homeostasis. Progr Neurobiol 1991;37:255-285.
24. 3H]-glutamate recognition site in synaptic plasma membranes. J Neurochem 1987;48:1699-1708.
25. 3H]-glycine recognition site as a modulatory site of the N-methyl-D-aspartate receptor complex. J Neurochem 1989;53: 370-375.
26. Nedergaard M. Mechanisms of brain damage in focal cerebral ischemia. Acta Neurol Scand 1988;77: 81-101.
27. Nurse S, Corbett D. Neuroprotection after several days of mild, drug-induced hypothermia. J Cereb Blood Flow Metab 1996;16:474-480.
28. O'Brien MD, Waltz AG. Transorbital approach for occluding the middle cerebral artery without craniectomy. Stroke 1973;4:201-206.
29. Ohno K, Okada M, Tsutsumi R, Kohara A, Yamaguchi T. Kainate excitotoxicity is mediated by AMPA-but not kainate-preferring receptors in embryonic rat hippocampal cultures. Neurochem Int 1997;31:715-722.
30. Okada M, Kohara A, Yamaguchi T. Characterization of YM90K, a selective and potent antagonist of AMPA receptors, in rat cortical mRNA-injected Xenopus oocytes. Eur J Pharmacol 1996;309:299-306.
31. Ozyurt E, Graham DI, Woodruff GN, McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 1988;8:138-143.
32. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. Focal cerebral ischaemia in the cat: Treatment with the glutamate antagonist MK-801 after induction of ischaemia. J Cereb Blood Flow Metab 1988;8: 757-762.
33. Pulsinelli W. Pathophysiology of acute ischemic stroke. Lancet 1992;339:533-536.
34. Shimizu-Sasamata M, Kawasaki-Yatsugi S, Okada M, et al. YM90K: Pharmacological characterization as a selective and potent α-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist. J Pharmacol Exp Ther 1996;276:84-92.
35. Shimizu-Sasamata M, Kano T, Rogowska J, Wolf GL, Moskowitz MA, Lo EH. YM872, a highly water soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after focal ischemia in rats. Stroke 1998;29:2141-2148.
36. Shiraishi K, Sharp FR, Simon RP. Sequential metabolic changes in rat brain following middle cerebral artery occlusion: A 2-deoxyglucose study. J Cereb Blood Flow Metab 1989;9:765-773.
37. Siesjö BK. Cell damage in the brain: A speculative synthesis. J Cereb Blood Flow Metab 1981;1:155-185.
38. Siesjö BK, Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: A unifying hypothesis. J Cereb Blood Flow Metab 1989;9: 127-140.
39. Takahashi M, Ni JW, Kawasaki-Yatsugi S, et al. YM872, a novel selective α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats. J Pharmacol Exp Ther 1998;284:467-473.
40. Takahashi M, Ni JW, Kawasaki-Yatsugi S, et al. Neuroprotective efficacy of YM872, an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats. J Pharmacol Exp Ther 1998;287:559-566.
41. Takasago T, Peters EE, Graham DI, Masayasu H, Macrae IM. Neuroprotective efficacy of ebselen, an antioxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br J Pharmacol 1997;122:1251-1256.
42. Tamura A, Graham DI, McCulloch J, Teasdale GM. Focal cerebral ischemia in the rat: Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab 1981;1:53-60.
43. Uematsu D, Greenberg JH, Reivich M, Hickey WF. Direct evidence for calcium-induced ischemic and reperfusion injury. Ann Neurol 1989;26:280-283.
44. Uematsu D, Greenberg JH, Hickey WF, Reivich M. Nimodipine attenuates both increase in cytosolic free calcium and histologic damage following focal cerebral ischemia and reperfusion in cats. Stroke 1989; 20:1531-1537.
45. Uematsu D, Araki N, Greenberg JH, Sladky J, Reivich M. Combined therapy with MK-801 and nimodipine for protection of ischemic brain damage. Neurology 1991;41:88-94.
46. Verdoorn TA, Burnashev N, Monyer H, Seeburg PH, Sakmann B. Structural determinants of ion flow through recombinant glutamate receptor channels. Science 1991;252:1715-1718.
47. Weisskoff RM, Chesler D, Boxerman J, Rosen BR. Pitfalls in MR measurement of tissue blood flow with intravascular tracers: Which mean transit time? Magn Reson Med 1993;29:553-559.
48. Wong LA, Kemp JA. Sites for antagonism on the N-methyl-D-aspartate receptor channel complex. Annu Rev Pharmacol Toxicol 1991;31:401-425.
49. Xue D, Huang ZG, Smith KE, Buchan AM. Immediate or delayed mild hypothermia prevents focal cerebral infarction. Brain Res 1992;587:66-72.
50. Xue D, Huang ZG, Barnes K, Lesiuk HJ, Smith KE, Buchan AM. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J Cereb Blood Flow Metab 1994;14:251-261.
51. Yatsugi S, Takahashi M, Kawasaki-Yatsugi S, et al. Neuroprotective effect of YM90K, a novel AMPA/kainate receptor antagonist, in focal cerebral ischemia in cats. J Cereb Blood Flow Metab 1996;16:959-966.